Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Injectables For HIV? ViiV And Janssen Show The Way

This article was originally published in Scrip

Executive Summary

The prospect of using long-acting injections rather than daily pills to suppress HIV has come a step closer with data presented from the LATTE-2 study suggesting that injections of ViiV Healthcare's cabotegravir together with Janssen's rilpivirine have comparable antiviral activity to a standard three-drug oral regimen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register